After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Avidity Biosciences Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Avidity Biosciences Inc is $4.24B. A total of 1.81 million shares were traded on the day, compared to an average of 1.46M shares.
In the most recent transaction, Boyce Sarah sold 28,000 shares of RNA for 39.93 per share on Jul 09 ’24. After the transaction, the President and CEO now owns 205,043 company shares. In a previous transaction on Jun 20 ’24, LEVIN ARTHUR A sold 5,000 shares at 37.59 per share. RNA shares that Director owns now total 14,830.
Among the insiders who sold shares, Boyce Sarah disposed of 32,074 shares on Jun 18 ’24 at a per-share price of $39.13. This resulted in the President and CEO holding 142,543 shares of RNA after the transaction. In another insider transaction, MacLean Michael F sold 11,228 shares at $39.13 per share on Jun 18 ’24. Company shares held by the Chief Financial Officer now total 57,865.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, RNA has a high of $42.79 and a low of $4.82.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RNA’s latest balance sheet shows that the firm has $405.54M in Cash & Short Term Investments as of fiscal 2021. There were $11.73M in debt and $29.66M in liabilities at the time. Its Book Value Per Share was $8.69, while its Total Shareholder’s Equity was $381.43M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Buy with a score of 4.89.
